Compass Therapeutics (CMPX) Net Cash Flow (2018 - 2026)
Compass Therapeutics (CMPX) posted Net Cash Flow of $24.5 million for Q1 2026, up 257.52% sequentially from -$15.6 million in Q4 2025, and up 1107.19% YoY from $2.0 million in Q1 2025.
Compass Therapeutics (CMPX) Net Cash Flow (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at $24.5 million in Q1 2026.
- Quarterly Net Cash Flow rose 1107.19% year-over-year to $24.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 million (down 18.73% YoY) and the FY2025 annual result came in at -$12.8 million, down 166.68% from the prior year.
- Net Cash Flow advanced to $24.5 million in Q1 2026 per CMPX's latest filing, from -$15.6 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $24.5 million in Q1 2026 and troughed at -$110.1 million in Q2 2022.
- A 5-year average of -$5.3 million and a median of -$4.3 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2026: Net Cash Flow plunged 1206.85% in 2022, then surged 1107.19% in 2026.
- Over 5 years, Net Cash Flow stood at $18.5 million in 2022, then tumbled by 133.57% to -$6.2 million in 2023, then surged by 198.64% to $6.1 million in 2024, then plunged by 354.65% to -$15.6 million in 2025, then surged by 257.52% to $24.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $24.5 million, -$15.6 million, and $23.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | -19.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.72 Mn |
| Jun 30, 2026 | -19.72 Mn |
| Mar 31, 2026 | 24.53 Mn |
| Mar 31, 2026 | 24.53 Mn |
| Dec 31, 2025 | -15.57 Mn |
| Dec 31, 2025 | -15.57 Mn |
| Sep 30, 2025 | 23.36 Mn |
| Sep 30, 2025 | 23.36 Mn |
| Jun 30, 2025 | -18.19 Mn |
| Jun 30, 2025 | -18.19 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Dec 31, 2024 | 6.11 Mn |
| Dec 31, 2024 | 6.11 Mn |
| Sep 30, 2024 | 17.97 Mn |
| Sep 30, 2024 | 17.97 Mn |
| Jun 30, 2024 | -4.27 Mn |
| Jun 30, 2024 | -4.27 Mn |
| Mar 31, 2024 | -554,000.00 |
| Mar 31, 2024 | -554,000.00 |